Medtronic today presented findings from a European trial testing the effectiveness of the CoreValve ReValving system, a percutaneous aortic stenosis repair device, in a subclavian approach for people who were at risk if the femoral approach would have been used.
The data reported procedural success of 100 percent; 24-hour survival of 100 percent; and 30-day survival of 89 percent. The available 30-day analysis also demonstrated clinical improvement in heart failure symptoms with 76 percent of the patients gaining at least a one-stage NYHA class and one-third improving by at least two stages.
Medtronic’s market-leading CoreValve system was designed to allow the implant of a replacement heart valve in patients with aortic stenosis who are at high or prohibitive surgical risk. The system enables a catheter-based implant via a peripheral blood vessel, traditionally the femoral artery. A significant subset of patients, however, have compromised peripheral arteries, which prevents the use of the femoral approach. Uniquely, the delivery system of the CoreValve device is small enough to allow an alternative approach via the subclavian artery beneath the collar bone.
The Medtronic CoreValve® System is designed to replace a diseased native aortic heart valve without open heart surgery and without concomitant surgical removal of the failed native valve. The system is comprised of an aortic tissue valve on a self-expanding frame, an 18 French size delivery catheter, and a disposable loading system. Each component of the system has been designed to meet the requirements of a percutaneous implantation approach.
Since the early 1960s, valve replacement surgery has extended the lives of people with failing aortic heart valves. Valve replacement surgery currently requires accessing the chest and opening the heart. Unfortunately, many patients are simply too ill to be considered as candidates for this type of invasive surgery.
Working with leading interventional cardiologists and cardiac surgeons, the Medtronic CoreValve® System was designed to permit aortic valve replacement on a beating heart in a procedure that can be performed in the cardiac catheterization laboratory.
The latest advancements of this beating heart procedure have eliminated the need for special equipment and incisions required to access and support the heart. These advances make heart valve replacement available to patients previously ineligible for this life-saving therapy.
4#心超
The overall cost in Malaysia is about RM 150,000/ About 300,000 RMB.
The device itself costs about USD 35,000.
The cost is so high because it is still new & not yet accepted in many regions. I believe as the days go by & the procedure becomes more & more common , the cost will go down.
How much does it cost for a valve replacement or a CABG surgery in China?
|关于我们|业务合作|手机版|新青年麻醉论坛
( 浙ICP备19050841号-1 )
发表于 2009-12-14 14:20:58
QQ好友和群
收藏
淘帖
鲜花
鸡蛋
提升卡
置顶卡
变色卡
楼主
发表于 2009-12-24 13:14:28
